|
|
Article: Acadia, Critical Therapeutics Price In 'Not A Robust Market'.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Senior Staff Writer
Two more biotech companies went public Thursday, but as has been the case lately, their offerings brought in less than first expected.
Critical Therapeutics Inc. and Acadia Pharmaceuticals Inc. priced their initial public offerings, raising $42 million and $35 million, respectively. Upon filing for their IPOs about two months ago, though, each projected significantly higher amounts - $103.5 million for Critical Therapeutics and $86.25 million for Acadia. Their pricings represent the 14th and 15th biotech IPOs of the year in the U.S., and nine other companies previously priced below their range, as well.
"This is not a robust ...
Related newspaper, magazine, and journal articles:
|
|
Article: COMPANY FORGING AHEAD WITH DIABETES DRUG AMYLIN STOCK DROPS 77 ...
BIOWORLD Today;
October 22, 1998 ;
700+ words
... ... price dropped below $8.50. (See BioWorld Today, Aug. 19, 1997, p. 1.) Along ... U.S. and Europe," Krawiec told BioWorld Today. Tanner said Amylin's move to continue ... J $36 million from a loan. (See BioWorld Today, March 3, 1998, p. 1.) Terms ...
|
|